Monoclonal antibody · Kills target cells, directed at CD20 (MS4A1) · developed by Tg Therapeutics
Ublituximab is a CD20-directed cytolytic monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes. Binding leads to B-cell lysis through antibody-dependent cellular cytolysis and complement-dependent cytolysis. It is studied in multiple sclerosis, including relapsing-remitting disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 19, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07225361 | Phase 4 | Multiple Sclerosis | Recruiting | TGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Updated Nov 1, 2026.